Document Detail


Clobazam : in patients with Lennox-Gastaut syndrome.
MedLine Citation:
PMID:  23034582     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Clobazam, as with other benzodiazepines, has a long history of use in the treatment of epilepsy. More recently, it was approved in the USA as adjunctive therapy for the treatment of seizures associated with Lennox-Gastaut syndrome in patients aged ≥2 years. In the pivotal, placebo-controlled CONTAIN trial in paediatric and adult patients with Lennox-Gastaut syndrome (n = 217 evaluable), adjunctive therapy with clobazam 5-40 mg/day for 12 weeks significantly reduced mean weekly drop seizure rates from baseline compared with adjunctive placebo (primary endpoint), with a significant dosage-dependent improvement in these rates. Results from a dosage-ranging, double-blind, multi-centre, phase II trial add further support for the efficacy of clobazam in paediatric and adult patients with Lennox-Gastaut syndrome (n = 61 evaluable). Improvements in mean weekly drop seizure rates with adjunctive clobazam treatment in these short-term trials was maintained in an ongoing, open-label extension study, with a 91.6 % reduction in mean weekly drop seizure rates from baseline (at randomization in the initial trials) to 24 months in the overall population. Treatment with adjunctive clobazam was generally well tolerated in these clinical trials and after at least 2 years of treatment in an open-label extension study. Most adverse events were mild or moderate and similar to those typically observed with other benzodiazepines.
Authors:
Lily P H Yang; Lesley J Scott
Publication Detail:
Type:  Journal Article; Review    
Journal Detail:
Title:  CNS drugs     Volume:  26     ISSN:  1172-7047     ISO Abbreviation:  CNS Drugs     Publication Date:  2012 Nov 
Date Detail:
Created Date:  2012-11-09     Completed Date:  2013-04-08     Revised Date:  2013-12-05    
Medline Journal Info:
Nlm Unique ID:  9431220     Medline TA:  CNS Drugs     Country:  New Zealand    
Other Details:
Languages:  eng     Pagination:  983-91     Citation Subset:  IM    
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Administration, Oral
Anticonvulsants / administration & dosage,  adverse effects,  pharmacokinetics,  therapeutic use*
Benzodiazepines / administration & dosage,  adverse effects,  pharmacokinetics,  therapeutic use*
Biological Availability
Humans
Intellectual Disability / drug therapy*
Randomized Controlled Trials as Topic
Spasms, Infantile / drug therapy*
Treatment Outcome
Chemical
Reg. No./Substance:
0/Anticonvulsants; 12794-10-4/Benzodiazepines; 2MRO291B4U/clobazam

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Metal-insulator transition in V(1-x)W(x)O(2): structural and electronic origin.
Next Document:  Sublingual Zolpidem (Edluar™; Sublinox™).